Acetylcholinesterase inhibition dose–response modeling for chlorpyrifos and chlorpyrifos-oxon  by Reiss, Richard et al.
Regulatory Toxicology and Pharmacology 63 (2012) 124–131Contents lists available at SciVerse ScienceDirect
Regulatory Toxicology and Pharmacology
journal homepage: www.elsevier .com/locate /yr tphAcetylcholinesterase inhibition dose–response modeling for chlorpyrifos and
chlorpyrifos-oxon
Richard Reiss a,⇑, Barbara Neal a, James C. Lamb IV a, Daland R Juberg b
a Exponent, 1800 Diagonal Road, Suite 500, Alexandria, VA 22314, USA
bDow AgroSciences Indianapolis, IN, USA
a r t i c l e i n f o a b s t r a c tArticle history:
Received 15 December 2011
Available online 17 March 2012
Keywords:
Chlorpyrifos
Acetylcholinesterase
Benchmark dose0273-2300 2012 Elsevier Inc.
http://dx.doi.org/10.1016/j.yrtph.2012.03.008
⇑ Corresponding author.
E-mail address: rreiss@exponent.com (R. Reiss).
1 We use the term organophosphate (OP) to ref
insecticides. However, it is noted that the strict deﬁni
applies to esters of phosphoric acid. Chlorpyrifos could
to as an organophosphorothioate.
Open access under CC BYThis paper evaluates new data for cholinesterase inhibition with chlorpyrifos (CPF). Marty et al. (2012)
recently conducted a CPF cholinesterase inhibition study in rats that included testing of males and
females, dosing by gavage or diet, administration in corn oil or milk, and with pups and adults. Addition-
ally, the study included cholinesterase inhibition testing for CPF-oxon, the active moiety that inhibits
cholinesterase. The study included 5–6 dose groups with eight animals/sex/group for most of the tests.
This paper provides a benchmark dose (BMD) analysis of the data from Marty et al. (2012), including a
BMD meta-analysis that includes CPF cholinesterase inhibition data from different assays within the
Marty et al. (2012) study and, in one case, from another study. From the meta-analysis, the recommended
BMD10s, based on brain acetylcholinesterase inhibition, are 1.7 mg/kg/day (BMDL10 = 1.3 mg/kg/day) for
acute doses to children and adults, and 0.67 mg/kg/day (BMDL10 = 0.53 mg/kg/day) for repeat doses to
children and adults. At the dose levels considered in this analysis, there was no evidence of a difference
in responses between males and females, corn oil versus milk administration, or pups versus adults. The
data on pups versus adults show that an extra safety factor to protect the young is not needed for CPF. CPF
data from the literature suggest that brain cholinesterase inhibition is the most appropriate metric for
cholinesterase inhibition risk assessment.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Chlorpyrifos (CPF) is a widely used organophosphate insecti-
cide. Organophosphates (OPs) are regulated by the United States
Environmental Protection Agency (US EPA) and other international
agencies based on the inhibition of acetylcholinesterase (AChE).1 A
recent EPA report to its Scientiﬁc Advisory Panel (SAP) noted limita-
tions in the available AChE datasets for CPF (US EPA, 2008). The SAP
reported that the lowest dose in the studies they considered was
0.3 mg/kg/day, which is threefold higher than the point-of-departure
(PoD) recommended by the SAP. Furthermore, the lower limit of the
benchmark doses (BMDs) corresponding to 10% AChE inhibition
(AChEI) for many of the gestational and postnatal studies were
approximately 10-fold lower than the lowest dose (1 mg/kg/day)
in the studies used to estimate the BMDs. However, BMD estimates
from studies without doses that are in the approximate range of theer to all organophosphorous
tion of organophosphate only
more speciﬁcally be referred
-NC-ND license.BMD may have large uncertainties, and it was considered appropri-
ate to develop data to better estimate the BMD for CPF.
Marty et al. (2012) recently conducted a new CPF cholinesterase
study that extended the dosing regimen to lower doses than have
previously been considered. This extended dose range provides
data closer to the 5–10% AChE inhibition range that is of interest
in BMD modeling. The study also included testing AChE inhibition
by CPF-oxon, which is a metabolic product of CPF and is the active
moiety that inhibits AChE following CPF exposure (e.g., Chambers
and Chambers, 1989). This paper analyzes AChE data from the
Marty et al. (2012) study to determine PODs for risk assessment
using BMD methods. In addition, the paper evaluates data from
several other CPF studies that measured AChE inhibition and con-
ducts a BMD meta-analysis among these studies (where reliable
and appropriate data are available) and the Marty et al. (2012)
study.
2. Materials and methods
2.1. Marty et al. (2012) study
The comparative cholinesterase study by Marty et al. (2012)
included measurements of brain and red blood cell (RBC) AChE,
and plasma butyrylcholinesterase (BuChE) for chlorpyrifos and
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given that BuChE is chemically distinct from AChE and BuChE inhi-
bition is not used as an adverse effect by US EPA in its organophos-
phate risk assessments (US EPA, 2006a). Throughout the paper, we
make speciﬁc references toAChE, butwill use the term ‘‘cholinester-
ase’’ to refer generally to AChE and BuChE. Cholinesterase activity
was measured using the standard international unit: an interna-
tional enzymeunit per liter (U/L) is deﬁned as the activity of enzyme
that converts 1 lmol/L of substrate in one minute at standard
conditions.
The study included four phases: (1) a range-ﬁnding study to
determine the approximate doses necessary to cause marked
(50–60%) brain AChE inhibition (AChEI) in young adult female
rats, (2) a time-of-peak effect study that determined the time after
dosing when peak AChE inhibition occurred across rats of different
ages and different modes of administration, (3) a deﬁnitive acute
dosing study with Post-Natal Day (PND) 11 and adult rats, includ-
ing bolus gavage dosing of CPF and CPF-oxon in corn oil for both
pups and adult rats, a dietary dosing study for adult rats, and a milk
vehicle study for pups, and (4) a deﬁnitive repeated dosing study
with PND 11 and adult rats, including bolus dosing for CPF and
CPF-oxon in corn oil.
The deﬁnitive acute and repeated dosing studies (phases 3 and
4) were conducted at the time-of-peak AChEI determined in the
phase 2 studies, with the exception of the dietary dosing study,
which was sampled at a toxicokinetically determined time-of-peak
effect. Table 1 summarizes the different experiments within the
study and the dosing regimen for each experiment. These data pro-
vide an excellent basis for BMD analysis given the number of dose
groups (5–6 in most tests). For repeat-dose exposures to CPF-oxon,
however, only two dose groups were used and the ﬁrst dose
(0.01 mg/kg/day) was very low and yielded minimal inhibition.
Therefore, these data were not appropriate for BMD analysis.
Marty et al. (2012) provides a detailed description of the study
and data.
2.2. Other CPF acetylcholinesterase data
For its SAP analysis, US EPA performed a literature search and
identiﬁed several other studies that measured CPF AChEI (US
EPA, 2008). The studies considered by US EPA were Betancourt
and Carr (2004), Hoberman (1998a,b), Mattsson et al. (1998,
2000), Maurissen et al. (2000), Moser et al. (2006), Timchalk
et al. (2006), and Zheng et al. (2000). US EPA was able to obtain
raw data for each of the studies. Table 2 summarizes the rat strain,
and dosing, and the groups of rats with AChEI measurements. TheTable 1
Summary of cholinesterase measurements in Marty et al. (2012).
Subpopulation Chemical Duration Dosin
PND 11 males CPF Acute Gavag
PND 11 females CPF Acute Gavag
PND 11 males CPF Acute Gavag
PND 11 females CPF Acute Gavag
Adult females CPF Acute Gavag
Adult females CPF Acute Diet
PND 11–21 males CPF 10 days Gavag
PND 11–21 females CPF 10 days Gavag
Adult females CPF 10 days Gavag
PND 11 males CPF-oxon Acute Gavag
PND 11 females CPF-oxon Acute Gavag
Adult females CPF-oxon Acute Gavag
PND 11–21 males CPF-oxon 10 days Gavag
PND 11–21 females CPF-oxon 10 days Gavag
Adult females CPF-oxon 10 days Gavag
a Doses in milk were adjusted for actual versus nominal doses because the actual
predominantly greater than 90–95% of the nominal dose.studies include rats at various stages of development (i.e., ranging
from PND 1 through PND 17, and into adulthood, and single and re-
peated doses).
An additional literature search was conducted to identify other
potentially relevant data. The criteria for selection were that AChEI
was measured at the time of peak effect, the raw AChE data were
available, the study was published in the last decade, and, ideally,
the study included at least four dose groups (including the control
group). A few studies were identiﬁed that met some of these crite-
ria and provided useful information, including Tang et al. (1999),
Richardson and Chambers (2004) and Carr et al. (2001). Tang
et al. (1999) provided brain AChE inhibition data for pups from dif-
ferent ages from PND 6 through PND 40. The data show that brain
AChE activity nearly doubles (in control animals) from PND 6 to
PND 22. Inhibition appears to decline as rats age past PND 30. Rich-
ardson and Chambers (2004) measured brain AChE inhibition at
PND 1, 3, and 6 for rats exposed in utero from gestation days
6–20. The inhibition was considerably less than observed for rats
directly dosed at PND 1 in Betancourt and Carr (2004). Carr et al.
(2001) measured forebrain and hindbrain AChE inhibition at differ-
ent ages between PND 6 and 30. We do not have the raw data from
any of these studies; therefore, they were considered only qualita-
tively in our analysis.2.3. Benchmark dose estimation methodology
BMDs were estimated using EPA’s methodology for organo-
phosphates as outlined in US EPA (2006a). The general dose–re-
sponse model is an exponential declining curve of the following
form:
AChE ¼ A PB þ ð1 PBÞ  exp
log 1PBBMR1PB
 
BMD
 Dose
0
@
1
A
2
4
3
5 ð1Þ
where: AChE = acetylcholinesterase activity, A = level of acetylcho-
linesterase activity in the absence of exposure to the organophos-
phate, PB = fraction of acetylcholinesterase activity remaining at a
very high dose of the organophosphate, BMR = level of inhibition
at which to estimate the benchmark dose (e.g., 0.10 for a 10 percent
inhibition), BMD = benchmark dose, Dose = dose of the chemical,
exp = base e of the natural logarithm, log = natural logarithm.
A ﬁxed effects model was used with the intercept A, PB terms
and BMDs estimated separately for males and females. A power
function was used to model heteroscedasticity (i.e., differences in
the variance across groups). It was difﬁcult to simultaneously ﬁtg Vehicle N Dose groups
e Corn oil 8 0, 0.05, 0.1, 0.5, 2, 5
e Corn oil 8 0, 0.05, 0.1, 0.5, 2, 5
e Milka 8 0, 0.04, 0.08, 0.41, 1.6, 4.0
e Milka 8 0, 0.04, 0.08, 0.41, 1.6, 4.0
e Corn oil 8 0, 0.05, 0.1, 0.5, 2, 10
n/a 8 0, 0.05, 0.1, 0.5, 2, 10
e Corn oil 8 0, 0.05, 0.1, 0.5, 1, 3.5
e Corn oil 8 0, 0.05, 0.1, 0.5, 1, 3.5
e Corn oil 8 0, 0.05, 0.1, 0.5, 1, 3.5
e Corn oil 8 0, 0.005, 0.01, 0.05, 0.1, 0.5
e Corn oil 8 0, 0.005, 0.01, 0.05, 0.1, 0.5
e Corn oil 8 0, 0.01, 0.05, 0.1, 0.5, 1
e Corn oil 8 0, 0.01, 0.5
e Corn oil 8 0, 0.01, 0.5
e Corn oil 8 0, 0.01, 0.5
doses were about 80% of the nominal. For other pathways, the actual dose was
Table 2
Summary of additional studies with cholinesterase inhibition measurements for chlorpyrifos.
Study Rat strain Dosing RBC measurements Brain measurements
Betancourt and Carr (2004) Sprague–Dawley Oral gavage in corn oil PND 1 (single dose)
PND 1–3 (repeated dose)a
PND 1–6 (repeated dose)a
Hoberman (1998a,b) Sprague–Dawley Oral gavage in corn oil GD 6–20 Dams (repeated dose) GD 6–20 Dams (repeated dose)
Mattsson et al. (2000) Sprague–Dawley Oral gavage in corn oil GD 6–20 Dams (repeated dose) GD 6–20 Dams (repeated dose)b
Moser et al. (2006) Long Evan Oral gavage in corn oil with 5% ethanol PND 17 (single dose)
Timchalk et al. (2006) Sprague–Dawley Oral gavage in corn oil PND 12 (single dose)
PND 17 (single dose)
PND 17 (single dose)
Zheng et al. (2000) Sprague–Dawley Oral gavage in peanut oil PND 5 (single dose
Adults (single dose)
PND 7–20 (repeated dose)
Adults (14 doses)
PND 5 (single dose)
Adults (single dose)
PND 7–20 (repeated dose)
Adults (14 doses)
a The raw data are unavailable; therefore, it was not included in the analysis.
b Includes hindbrain and forebrain measurements.
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and females by testing various combinations of PB for males and fe-
males and choosing the model with the highest maximum likeli-
hood. The 95th percentile lower statistical limit was estimated
from the regression coefﬁcient and standard error for the BMD
and is denoted as BMDL (lower limit of the BMD).
Brain AChE was modeled using an expanded model (US EPA,
2006a). In the expanded model, the Dose term in the general
dose–response model (Eq. (1)) was replaced by a ‘‘scaled internal
dose’’ (idose) as follows:
idose ¼ 0:5  fðDose S DÞ
þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðDose S DÞ2Þ þ 4  Dose  S
q
g ð2Þ
where S and D are constants that are ﬁt in the model. S, the shape
factor, controls the low-dose shape of the curve, and D, the displace-
ment factor, controls the ultimate horizontal displacement of the
curve. The expanded model provides an ‘‘elegantly simple’’ way,
in the words of the SAP, to improve the ﬁts for chemicals with min-
imal responses at low doses.
Following EPA’s methods in the cumulative risk assessment, the
general model was ﬁrst ﬁt with a ﬁxed effects model, including
both the male and female data for a single compartment. The
parameters A and BMD were modeled as ﬁxed effects and separate
estimates were made for males and females. Similarly, PB was
estimated separately for males and females by testing various
combinations of PB for males and females and choosing the model
with the highest maximum likelihood. Once the PB values were
obtained, the expanded model was tried. A grid search was made
to estimate the best ﬁt values of S and D. Continuous grid searches
were made, zeroing in on the model that provided the maximum
likelihood. A power function was used to model heteroscedasticity.
The Akaike Information Coefﬁcient (AIC) (Akaike, 1974) was used
to determine whether the simple or expanded model provides
the best ﬁt. The models were implemented in the R programming
language and adapted from EPA’s code.
The US EPA uses both brain and RBC AChEI in regulatory risk
assessments. Generally, the US EPA uses BMD10s for both brain
and RBC AChEI, corresponding to the statistical estimate of the
doses that cause a 10% inhibition. On at least one occasion, US
EPA used a BMD20 for RBC AChE where the RBC BMD20 was protec-
tive of brain AChE inhibition and other endpoints (US EPA, 2006b).
Therefore, BMD10s were estimated for brain and RBC AChE inhibi-
tion and a BMD20 was estimated for RBC AChEI.
To determine a value for risk assessment when reliable BMDs
are available across different studies, a standard meta-analysis
method was used – inverse-variance weighting (Borenstein et al.,
2009). For each BMD estimate, a weight is determined as:Wi ¼ 1Vi
where Vi is the variance associated with each BMD estimate, and i is
the ith BMD estimate. The grand mean BMD estimate is:
M ¼
Pk
i¼1WiYiPk
i¼1Wi
whereM is the BMD weighted-mean and Yi is the ith BMD estimate.
The variance of M is:
VM ¼ 1Pk
i¼1Wi
:
Meta-analysis, in this paper, is deﬁned as combining data across
studies and/or combining data across different assays within a sin-
gle study.
To compare pup and adult sensitivity, it is useful to estimate the
ratio of the adult-to-pup BMDs, as EPA does to estimate the Food
Quality Protection Act (FQPA) safety factor to account for increased
sensitivity for children compared to adults. Estimating the conﬁ-
dence intervals of a ratio analytically is complex (e.g., Beyene
and Moineddin, 2005). Therefore, the conﬁdence intervals were
estimated by calculating the BMD ratio 1000 times via Monte Carlo
simulation, randomly drawing from the BMD distribution using the
standard error of the BMD estimate and assuming normality
around the standard error. To verify that the simulation worked
correctly, the result was compared with Fieller’s approximation
method (Fieller, 1954). The agreement was excellent.3. Results
3.1. BMD modeling for Marty et al. (2012) study
Table 3 summarizes the BMD estimates for the Marty et al.
(2012) study. The dose–response ﬁts for all of the BMD estimates
are provided in the Supplementary information (S1). The RBC data
were ﬁt with the simple model, and the brain AChE data were best
ﬁt with the expanded model. Figs. 1 and 2 provide illustrative
examples of the model ﬁts. Fig. 1 shows the ﬁt for RBC AChEI for
an acute dose in milk to female PND 11 pups and provides an
example of the simple model. The dose–response ﬁt shows a sim-
ple exponential decline. Fig. 2 shows the ﬁt for brain AChEI for an
acute dose in milk to female PND 11 pups and provides an example
of the complex model. The ﬁt shows a low-dose shoulder of limited
inhibition to about 1.0 mg/kg followed by an exponential decline
thereafter. The estimates for BMD10 and BMDL10s are shown on
each of the ﬁgures.
Table 3
Benchmark doses for Marty et al. (2012). All BMD estimates are in mg/kg for acute doses and mg/kg/day for repeated doses. BMDLs are in parentheses.
Subpopulation Chemical Duration Dosing Vehicle RBC AChe Brain AChe
BMD10 BMD20 BMD10
PND 11 males CPF Acute Gavage Corn oil 0.45 (0.36) 0.94 (0.76) 2.1 (0.71)
PND11 females CPF Acute Gavage Corn oil 0.53 (0.41) 1.1 (0.87) 2.0 (0.70)
PND 11 males CPF Acute Gavage Milk 0.41 (0.27) 0.86 (0.56) 1.7 (0.70)
PND 11 females CPF Acute Gavage Milk 0.38 (0.25) 0.80 (0.52) 1.4 (0.52)
Adult females CPF Acute Gavage Corn oil 0.65 (0.52) 1.4 (1.1) 2.9 (0.92)
Adult females CPF Acute Diet n/a 0.30 (0.26) 0.63 (0.55) 4.6 (2.7)
PND 11–21 males CPF 10 days Gavage Corn oil 0.10 (0.08) 0.22 (0.17) 0.58 (0.34)
PND 11–21 females CPF 10 days Gavage Corn oil 0.17 (0.15) 0.37 (0.32) 0.65 (0.41)
Adult females CPF 10 days Gavage Corn oil 0.10 (0.09) 0.22 (0.19) 0.83 (0.49)
PND 11 males CPF-oxon Acute Gavage Corn oil 0.09 (0.07) 0.20 (0.15) >0.5
PND 11 females CPF-oxon Acute Gavage Corn oil 0.08 (0.07) 0.18 (0.14) >0.5
Adult females CPF-oxon Acute Gavage Corn oil 0.09 (0.07) 0.19 (0.15) >1.0
PND 11–21 males CPF-oxon 10 days Gavage Corn oil a a a
PND 11–21 females CPF-oxon 10 days Gavage Corn oil a a a
Adult females CPF-oxon 10 days Gavage Corn oil a a a
a There were only two treated groups for the oxon repeated dose groups, which is not sufﬁcient for BMD modeling.
Fig. 1. Chlorpyrifos BMD ﬁt for RBC cholinesterase for acute dosage in milk to
female PND 11 pups in the Marty et al. (2012) study. Note: Conﬁdence intervals are
the 95th percentile bounds on estimate of mean.
Fig. 2. Chlorpyrifos BMD ﬁt for brain cholinesterase for acute dosage in milk to
female PND 11 pups in the Marty et al. (2012) study. Note: Conﬁdence intervals are
the 95th percentile bounds on estimate of mean.
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ing brain AChE BMDs. For example, for PND 11 males exposed to
chlorpyrifos by gavage with corn oil (single dose), the estimated
BMD10 was 0.45 mg/kg (BMDL10 = 0.36 mg/kg) for RBC AChE inhi-
bition, while the brain AChE inhibition BMD10 was 2.1 mg/kg
(BMDL10 = 0.71 mg/kg). The BMD estimates were also compared
to ascertain differences between males and females, corn oil versus
milk vehicles, diet versus gavage dosing, pups versus adults, and
chlorpyrifos versus chlorpyrifos-oxon. Table 4 shows different
comparison results. To statistically compare two BMD estimates,
the ratio of the BMDs was calculated and the conﬁdence intervals
estimated as explained in the Materials and Methods section. If the
conﬁdence intervals overlapped with unity, the ratio was consid-
ered not statistically signiﬁcant. Of the seven comparisons be-
tween male and female BMDs, only one comparison was
statistically signiﬁcant (repeated dose for RBC AChE), with the
male-to-female ratios ranging from 0.59 to 1.2 across the seven
comparisons. Therefore, there are not likely to be any signiﬁcant
differences in AChE responses between males and females with
the possible exception of repeated dose exposures to CPF in cornoil for PND 11–21 pups for RBC AChE. There were no statistically
signiﬁcant differences for the four comparisons between corn oil
and milk vehicles in PND11 pups with the corn oil-to-milk BMD ra-
tio ranging from 1.1 to 1.4. The adult diet-to-gavage BMD ratio was
lower for RBC AChE (0.46, with conﬁdence interval of 0.37–0.60),
indicating statistically signiﬁcantly greater sensitivity following
dietary exposure. However, for brain AChE, the ratio was 1.6 (con-
ﬁdence interval, 0.75–5.1), and while not statistically signiﬁcant,
was elevated and in the direction opposite of that of the RBC ratio,
indicating possibly greater sensitivity following gavage exposure
for brain AChE. This sensitivity difference is likely caused by phar-
macokinetic differences in the rate of delivery to the blood and the
brain for the two routes of administration.
The ratio of adult-to-pup BMDs ranged from 0.59 to 1.5, with
the only statistically signiﬁcant comparison being for the ratio of
repeated doses adults compared to pups for CPF for RBC AChE,
where the ratio was 0.59 (0.50–0.69). In addition, the ratio indi-
cates a greater sensitivity for adults, which is contrary to the com-
mon hypothesis that the young are more susceptible to AChEI. The
Table 4
Comparison of different factors affecting BMD estimates in the Marty et al. (2012) study. BMDLs are in parentheses.
Comparison Population Compartment BMD10 ratio (95th conﬁdence interval)
Males-to-females Acute dose to CPF in corn oil vehicle for PND 11 pups RBC 0.85 (0.63–1.2)
Brain 1.0 (0.33–3.3)
Acute dose to CPF in milk vehicle for PND 11 pups RBC 1.1 (0.66–1.8)
Brain 1.1 (0.42–3.4)
Repeated dose to CPF in corn oil for PND 11–21 pups RBC 0.59 (0.56–0.74)
Brain 0.89 (0.49–1.6)
Acute dose to CPF-oxon in corn oil for PND 11 pups RBC 1.1 (0.86–1.4)
Brain n/aa
Corn oil-to-milk Acute dose to CPF for PND 11 RBC 1.1 (0.76–1.7)
Male pups Brain 1.2 (0.37–3.3)
Acute dose to CPF for PND 11 female pups RBC 1.4 (0.94–2.2)
Brain 1.4 (0.44–4.2)
Dietary-to-gavage Acute dose to CPF for adults RBC 0.46 (0.37–0.60)
Brain 1.6 (0.75–5.1)
Adults-to-pups Acute dose to CPF RBC 1.2 (0.91–1.7)
Brain 1.5 (0.41–4.5)
Repeated dose to CPF RBC 0.59 (0.50–0.69)
Brain 1.3 (0.69–2.3)
Acute dose to CPF-oxon RBC 1.1 (0.85–1.4)
Brain n/aa
CPF-to-CPF-oxon Acute dose to PND11 pups RBC 6.6 (5.0–8.5)
Brain n/aa
Acute dose to adults RBC 7.2 (5.3–9.8)
Brain n/aa
a BMDs could not be estimated due to insufﬁcient response at the highest dose.
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niﬁcant. Overall, these data are not consistent with a difference in
sensitivity between pups and adults.
Finally, a comparison was made between CPF and CPF-oxon. For
RBC, the parent-to-oxon ratio ranged from 6.6 (pups) and 7.2
(adults), and both comparisons were highly statistically signiﬁcant.
The CPF-oxon data were not adequate for BMD modeling for brain
AChE because the CPF-oxon did not inhibit brain AChE at doses up
to 0.5 mg/kg/day; therefore, quantitative estimates about the rela-
tive sensitivity of CPF and CPF-oxon for brain AChE inhibition
would be uncertain. In addition, the comparison of CPF to CPF-oxon
for RBC AChE is difﬁcult to interpret. CPF-oxon has an extremely
short half-life in rat blood of approximately 10 s (Brzak et al.,
1998). In addition, Munk et al. (2003) have shown that the mean
time for blood ﬂow from the aorta to the portal vein of the pig is
fairly slow, at 0.35–1.7 min (Munk et al., 2003). This slow blood
velocity is due to the increased cross-sectional area of the total
splanchnic capillary bed versus the larger primary blood vessels.
It is therefore conceivable that the RBC effects measured in this
and prior studies with CPF-oxon may represent a pre-systemic ef-
fect, not relevant for extrapolation to other tissues.2 It is possible that this issue is the result of some confusion between EPA and the
searchers regarding the data that was provided. For example, the variability in the
rain cholinesterase data is much less in the ﬁgures in the original paper compared to
e data archived by EPA.3.2. BMD modeling for literature studies
Table 2 summarizes the populations for which BMD measure-
ments were made across the literature studies. The measurements
include single dose tests for pups at PND 1 (Betancourt and Carr,
2004), PND 5 (Zheng et al. (2000)), PND 12 (Timchalk et al.,
2006), and PND 17 (Moser et al., 2006; Timchalk et al., 2006).
The Marty et al. (2012) study provided a single dose measurement
at PND 11. Thus, the additional literature provides a range of older
and younger pups, as well as similar ages to those tested by Marty
et al. (2012). For repeated doses, two studies provide measure-
ments for dams of exposures through gestation day (GD) 6–20
(Hoberman, 1998a,b; Mattsson et al., 2000). The Zheng et al.
(2000) study provides repeated dose data for non-pregnant adults
and PND 7–20 pups (compared to PND 11–21 pups for Marty et al.
(2012)).The BMD estimates for the literature studies are summarized in
Table 5. As with the Marty et al. (2012) estimates, the Supplemen-
tary information includes all of the dose–response plots (S2). The
next section will provide a meta-analysis among the assays in
the Marty et al. (2012) study and, where appropriate, include data
from the literature studies.3.3. Meta-analysis
3.3.1. Acute dose to pups
There are estimates of BMDs for acute doses to pups from ﬁve
studies, including Marty et al. (2012), Betancourt and Carr
(2004), Zheng et al. (2000), Moser et al. (2006), and Timchalk
et al. (2006). The age of the pup is important relative to AChEI
(e.g., Tang et al., 1999). The Marty et al. (2012) study measured
AChE at PND 11. PND 11 is an ideal time point to consider for
extrapolating rat assay results to risk assessment for children. Un-
like humans, the rodent central nervous system predominantly
matures post-natally and the permeability of the blood brain bar-
rier decreases signiﬁcantly through PND 10 (Williams and DeSesso,
2010). The Zheng et al. (2000) measurement at 5 days and the Tim-
chalk et al. (2006) measurement at PND 17 are too far from PND 11
to combine in a meta-analysis. While the Timchalk et al. (2006)
measurement at PND 12 is close enough to include in a meta-anal-
ysis with the PND 11 data for Marty et al. (2012), the Timchalk
et al. (2006) study included only two treated groups, which renders
non-linear regression analysis uncertain, particularly for brain
AChE where the model has separate shapes at low and high doses.
Therefore, the Timchalk et al. (2006) were not used in the BMD
analysis. In addition, US EPA raised some reliability issues with
the Zheng et al. (2000) data, given high variability in the controls
(US EPA, 2008)2; therefore, Zheng et al. (2000) was not included in
the meta-analysis, although the results of Zheng et al. (2000) were
compared with the meta-analysis results.re
b
th
Table 5
BMD estimates for literature studies and studies in regulatory database (prior to Marty et al.). All BMD estimates are in mg/kg for acute doses and mg/kg/day for repeated doses.
BMDLs are in parentheses.
Study Population Benchmark dose
RBC BMD10 RBC BMD20 Brain BMD10
Betancourt and Carr (2004) PND 1 (single dose) 0.19 (0.16)
Hoberman (1998a,b) GD 6–20 dams (repeated dose) 0.06 (0.03) 0.12 (0.07) 0.89 (0.32)
Mattsson et al. (2000) GD 6–20 dams (repeated dose) 0.07 (0.05) 0.15 (0.11) Hindbrain: 1.0 (0.43)
Forebrain: 1.1 (0.37)
Moser et al. (2006) PND 17 (single dose) 1.9 (0.42)
Timchalk et al. (2006) PND 12 (single dose) 0.31 (0.20) 0.68 (0.44)
PND 17 (single dose) 1.1 (0.94) 2.4 (2.0) 0.64 (0.58)
Zheng et al. (2000) PND 5 (single dose) 0.32 (0.27) 0.68 (0.58) 1.2 (0.33)
Adults (single dose) 0.62 (0.58) 1.3 (1.2) 3.8 (0.7)
PND 7–20 (repeated dose) 0.20 (0.11) 0.42 (0.24) 0.96 (0.30)
Adults (14 doses) 0.06 (0.05) 0.13 (0.11) 0.87 (0.39)
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PND 1 is much lower than the comparable BMDs at PND 11. How-
ever, PND 1 pups are equivalent in development to in utero human
exposure (US EPA, 2006b), which raises questions about the
relevance of these data for human risk assessment. The Richardson
and Chambers (2004) data are useful for assessing in utero expo-
sure. In the Marty et al. (2012) study, the pups were exposed in ute-
ro through direct dosing of the dam. The pup response was
substantially less than in Betancourt and Carr (2004). Because of
the limited relevance of rat PND 1 data (i.e., rat developmental
stage closer to in utero for humans) and the result from Richardson
and Chambers (2004) showing no inhibition for in utero exposure,
the Betancourt and Carr (2004) data were not included in the
meta-analysis.
As such, the meta-analysis was performed only with the Marty
et al. (2012) data. The meta-analysis was performed across the
male and female and corn oil and milk data, because the differ-
ences in individual measurements were not statistically signiﬁcant
across sex and vehicle. The BMD20 for RBC AChE was 1.1 mg/kg
(BMDL20 = 0.9 mg/kg). For brain AChE, the estimated BMD10 was
1.7 mg/kg (BMDL10 = 1.3 mg/kg).
3.3.2. Acute dose to adults
BMD estimates for acute doses of CPF to adults are available
fromMarty et al. (2012) and Zheng et al. (2000). The data for Marty
et al. (2012) are available for gavage and dietary routes of expo-
sures, but given the non-signiﬁcant differences in results, these
data were combined for meta-analysis. The meta-analysis was per-
formed with the Marty et al. (2012) data; however, it is noted that
the BMDs obtained by Zheng et al. (2000) are consistent with the
Marty et al. (2012) results for gavage in corn oil.
As noted earlier, the Marty et al. (2012) BMDs for gavage in corn
oil were lower for brain AChE inhibition and higher for RBC AChE
inhibition compared to diet. Given that brain AChE inhibition is
the most toxicologically relevant (see later discussion), the BMDs
derived from the gavage in corn oil study are recommended for risk
assessment to be conservative relative to dietary BMDs.
3.3.3. Repeated dose to pups
Three studies have available data for repeated doses of CPF to
pups: Marty et al. (2012), Zheng et al. (2000), and Betancourt
and Carr (2004). The data are relatively consistent among the three
studies, even though they span different exposure periods in rat
development. For RBC, the BMD20s were 0.22 mg/kg/day (males)
and 0.36 mg/kg/day (females) in the Marty et al. (2012) study,
while the RBC BMD20 from Zheng et al. (2000) (females) was
0.42 mg/kg/day (Betancourt and Carr, 2004, included only brain
AChE measurements). Given the reliability issues associated with
the Zheng et al. (2000) measurements, the more robust Martyet al. (2012) RBC BMD20s are preferred. Performing a meta-analysis
of the male and female values yields an RBC BMD20 of 0.30 mg/kg/
day and a BMDL20 of 0.26 mg/kg/day.
For brain AChE, the Marty et al. (2012) BMD10 estimates were
0.58 mg/kg/day for males and 0.65 mg/kg/day for females. The
Zheng et al. (2000) BMD10 was higher at 0.96 mg/kg/day, while
the Betancourt and Carr (2004) BMD10 estimates were lower at
0.44 mg/kg/day for PND 1–3 and 0.41 mg/kg/day for PND 1–6.
Again, given the questionable reliability of Zheng et al. (2000)
and the early life stage of Betancourt and Carr (2004) which is
equivocally relevant to human risk assessment, the Marty et al.
(2012) values are preferred for assessing toxicity to PND 11 rats.
Performing a meta-analysis between the male and female value
yields a brain BMD10 of 0.62 mg/kg/day and a BMDL10 of
0.46 mg/kg/day. The results are broadly consistent with Tang
et al. (1999).
3.3.4. Repeated dose to adults
Four studies included BMDs for repeated doses to adults: Marty
et al. (2012), Zheng et al. (2000), Hoberman (1998a,b), and Matts-
son et al. (1998, 2000). The results were similar across the studies.
Another point is evident from a review of these data. Two of the
studies included measurements for non-pregnant adults and two
included measurements for dams. Despite that difference, the
BMDs were remarkably similar and particularly so for brain AChE,
indicating that pregnancy likely does not affect the response to
CPF. This also shows that BMD analysis is very helpful for compar-
ing effect levels across studies with differing dose groups.
For RBC, the BMD20s were 0.22 mg/kg/day (Marty et al., 2012),
0.13 mg/kg/day (Zheng et al., 2000), 0.12 mg/kg/day (Hoberman,
1998a,b), and 0.15 mg/kg/day (Mattsson et al., 1998, 2000). A
meta-analysis was performed across Marty et al. (2012), Hoberman
(1998a,b) and Mattsson et al. (1998, 2000). The resulting BMD20
estimate was 0.16 mg/kg/day (BMDL20 = 0.13 mg/kg/day).
For the brain, the BMD10s were 0.83 mg/kg/day (Marty et al.,
2012), 0.87 mg/kg/day (Zheng et al., 2000), 0.89 mg/kg/day (Hober-
man, 1998a,b), and 1.0 mg/kg/day and 1.1 mg/kg/day in the Matts-
son et al. (1998, 2000) study for hindbrain and forebrain,
respectively. For the meta-analysis, the Marty et al. (2012) and
Hoberman (1998a,b) studies were used. The Mattsson et al.
(1998, 2000) study was excluded because the measurements were
not whole brain. The resultant meta-analysis BMD10 was 0.85 mg/
kg/day (BMDL10 = 0.55 mg/kg/day).
4. Discussion
For regulatory risk assessments, the results of the meta-analysis
are recommended. The BMDs are summarized in Table 6. Two
additional meta-analyses were performed. There was no statistical
130 R. Reiss et al. / Regulatory Toxicology and Pharmacology 63 (2012) 124–131difference between pups and adults, so a meta-analysis was per-
formed with the combined pup and adult dataset. For acute doses,
the meta-analysis resulted in a BMD20 for RBC AChE of 1.0 mg/kg/
day with a BMDL20 of 0.90 mg/kg/day, and a BMD10 for brain AChE
of 1.7 mg/kg/day with a BMDL10 of 1.3 mg/kg/day for brain AChE.
For repeated doses, the meta-analysis resulted in a BMD20 for
RBC AChE of 0.21 mg/kg/day with a BMDL20 of 0.19 mg/kg/day,
and a brain AChE BMD10 of 0.67 mg/kg/day with a BMDL10 of
0.53 mg/kg/day for brain AChE.
Several other results from this analysis are also relevant to reg-
ulatory risk assessment. Under the FQPA, US EPA requires all toler-
ance decisions to account for the special susceptibility of children
to pesticides. US EPA requires an additional ten-fold (10) safety
factor for risk assessments used in setting or reassessing food tol-
erances, and the default 10-fold safety factor can be replaced ‘‘only
if reliable data demonstrate that the resulting level of exposure
would be safe for infants and children’’ (US EPA, 2002a).
The chlorpyrifos database is unusually robust. Adult and juve-
nile effects have been well-characterized in multiple studies. The
Marty et al. (2012) study represents a thorough assessment of
the relative sensitivity of AChEI in adult and juvenile rats. If only
AChE is considered, the existing dataset is sufﬁciently reliable that
the FQPA factor can be adjusted to 1 for chlorpyrifos based on this
criterion.
It is noted that a number of earlier relatively high-dose studies
of chlorpyrifos have shown an increased sensitivity of pups com-
pared to either dams or adults to AChE inhibition from chlorpyri-
fos. However, Mattsson et al. (2000) reviewed a number of
studies with adult to pup comparisons of AChE inhibition and
noted ‘‘Direct exposure of nursing rats to single doses of CPF has
resulted in lethality, toxicity, and signiﬁcant inhibition of ChE at
appreciably lower doses than in adult rats. . . The differences in
sensitivity, however, appeared to be dose-related’’ (Mattsson
et al., 2000).
In addition, Dr. Carey Pope, in a 2001 letter to EPA, commented:
‘‘There appear to be three important factors contributing to age-re-
lated differences in sensitivity to chlorpyrifos: differences in bio-
transformation (detoxiﬁcation), differences in synaptic adaptation
(feedback inhibition of acetylcholine release), and differences in
target enzyme (acetylcholinesterase) recovery. These three factors
are differentially important, depending on the nature of dosing, i.e.,
acute, high dose or repeated low dose exposures. . . In summary, I
would argue that based on the laboratory rat model, young individ-
uals are more sensitive than adults to acute, high dosage chlorpyri-
fos exposures. . . With repeated dosing, however, in particular with
lower levels of exposures, the younger animal does not appear
higher in sensitivity to chlorpyrifos. Indeed, with intermittent
exposures, one could argue that the adult is more sensitive than
the younger animal to cumulative neurochemical alterations. . . It
would therefore seem prudent to consider the very important role
of exposure magnitude and frequency on age-related differences in
sensitivity to chlorpyrifos when conducting the risk assessment for
this pesticide.’’
Consistent with the conclusions of Pope (2001), the Marty et al.
(2012) study conﬁrms the lack of greater sensitivity of pups to re-
peated dose exposures and also shows a lack of relative sensitivity
to PND 11 pups to acute exposures; at low more environmentallyTable 6
Recommended BMDs for risk assessment. BMDLs are in parentheses.
Duration Benchmark dose
RBC BMD20 Brain BMD10
Acute dose (mg/kg) 1.0 (0.90) 1.7 (1.3)
Repeat dose (mg/kg/day) 0.21 (0.19) 0.67 (0.53)relevant doses there is no increased sensitivity of pups compared
to adults for either single or repeated doses. The BMD calculations
support the conclusion that the AChEI dose–response curve is well-
understood in young animals, and that at low relevant doses there
is no differential sensitivity between adults and the young.
Another signiﬁcant issue with AChE inhibition is the appropri-
ate metric for risk assessment. An important consideration is
whether brain AChE inhibition is adequately protective against
biologically signiﬁcant peripheral nerve AChEI. For many organo-
phosphate compounds, brain and RBC AChE, and BuChE are the
only available endpoints for analyses. As discussed below, this is
not the case for chlorpyrifos. BuChE is not considered toxicologi-
cally relevant (US EPA, 2000).
In the 2002 ‘‘Cumulative Risk Assessment for Organophos-
phates,’’ EPA makes two excellent points regarding why brain AChE
inhibition is a preferable endpoint to use as a point of departure
(PoD) for risk assessment (US EPA, 2002b). The most critical point
made by EPA is that brain AChEI is an actual measure of toxicity,
rather than a surrogate. RBC AChE provides a biological sink for
AChE inhibitors, but inhibition of RBC AChE is not an adverse effect,
other than the observation that saturation of this sink makes more
of the proximal toxicant available to react with AChE in other ac-
tual target tissues, such as the brain and peripheral nervous
system.
The second point made by EPA relates to variability of the end-
points. EPA stated, ‘‘Principally, compared to relative potency esti-
mates based on RBC, estimates of relative potency based on brain
ChE have tighter conﬁdence intervals and therefore will confer less
uncertainty on cumulative risk estimates. In addition, these data
represent a direct measure of the common mechanism of toxicity
as opposed to using surrogate measures’’ (US EPA, 2002b).
RBC AChE data are inherently variable, such that 20% inhibition
is considered a reasonable cutoff for determination of an effect
level. Therefore, a BMD20 is recommended as the appropriate anal-
ysis for RBC AChE data, as EPA did in at least one instance (US EPA,
2006b). Using brain AChE inhibition as the basis for a PoD also re-
duces uncertainty, with less variability, such that 10% inhibition
from control is considered an effect threshold (US EPA, 2002b).
Thus, a BMD10 can be calculated with more conﬁdence.
Chlorpyrifos data have been collected on the peripheral nervous
system, further supporting the use of the brain AChE data rather
than RBC AChE data for risk assessment. In contrast to many OPs,
chlorpyrifos has a rich database for evaluating the relative sensitiv-
ity of AChE in the brain and peripheral nervous system (PNS),
including extensive repeat-dose studies in the dog (Marable
et al., 2007) that were designed speciﬁcally to address this issue.
These dog studies clearly showed that PNS AChE is not more sen-
sitive than brain AChE.
Two separate repeated dose dietary studies were conducted in
dogs and reported by Marable et al. (2007). In the ﬁrst four week
study, male dogs (three per dose) were exposed to 0.0, 0.3, 0.6,
or 1.2 mg/kg/day chlorpyrifos. Mixed cholinesterase (mChE), AChE,
and BuChE activities were measured in plasma, RBC, brain, left at-
rium and ventricle, diaphragm, quadriceps, and nodose ganglia.
Plasma, brain and peripheral tissue BuChE and RBC AChE were
inhibited at all dose levels. Brain AChE and peripheral AChE activ-
ities were unaffected.
The second six-week exposure duration study exposed four
dogs/sex/dose by diet to 0.0, 0.5, 1.0, or 2.0 mg/kg/day CPF; the
same endpoints were evaluated as in the pilot study. No analyses
were done of mixed ChE or BuChE data. RBC AChE was statistically
signiﬁcantly inhibited at all doses in both sexes. AChE in dia-
phragm, quadriceps, and nodose ganglia were not different from
control in the dosed groups. Brain AChE was inhibited (approxi-
mately 6%) in high-dose males, and females. Left atrium AChE at
the high dose was inhibited 25.5% in males but activity was
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were attributed to chance because of the differences in response
between males and females, which were not markedly different
for other AChE parameters, and because of the lack of effects in
males in the pilot study on the same parameter. While peripheral
tissue and brain AChE were not affected following exposure to
1.0 mg/kg/day, RBC AChE was inhibited at all doses. The authors re-
ported that ‘‘. . . no peripheral tissue cholinesterase was identiﬁed
as more sensitive to inhibition by dietary [chlorpyrifos] than brain
cholinesterase’’ and concluded, ‘‘These data indicate that [chlor-
pyrifos] standards based upon inhibition of brain cholinesterase
will be protective of peripheral tissue cholinesterase.’’
The chlorpyrifos dog studies tested a wide range of PNS tissues
and clearly show that the brain AChE response was at least as
sensitive as PNS tissues and that the RBC AChE response was much
less than brain or PNS tissues. Based on these factors, use of brain
AChE inhibition to determine the PoD for chlorpyrifos is both
conservative and scientiﬁcally appropriate.5. Conclusions
This study demonstrates the use of BMD analysis to derive PoDs
for risk assessment for a study with numerous sub-measurements.
BMD analysis was also used to perform a meta-analysis across dif-
ferent assays within the Marty et al. (2012) study and, in one case,
across different studies. From the meta-analysis, the recommended
BMD10s for brain AChEI are 1.7 mg/kg/day (BMDL10 = 1.3 mg/kg/
day) for acute doses to adults and children, and 0.67 mg/kg/day
(BMDL10 = 0.53 mg/kg/day) for repeated doses to children and
adults. These values represent the most likely values from analyz-
ing the totality of the data and are the most reliable values for cho-
linesterase-based risk assessment. Additionally, there were no
sensitivity differences for AChEI between males and females, corn
oil versus milk vehicles, and pups versus adults. The last compari-
son suggests that an additional 10-fold FQPA safety factor is not
necessary for CPF to protect children because reliable data support
its elimination. Finally, literature data show that brain AChEI is the
appropriate metric for cholinesterase inhibition risk assessment for
chlorpyrifos.Conﬂict of interest statement
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